BTIG Reiterates Buy Rating on ORIC Pharmaceuticals, Keeps $26 Target

BTIG reiterated its Buy rating and $26 price target on ORIC Pharmaceuticals. The target implies 188.9% upside from the stock’s Oct. 27 close of $9.